{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T21:45:53Z","timestamp":1794260753137,"version":"4.9.0"},"reference-count":21,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Novel therapies are needed for myelofibrosis (MF), particularly after Janus kinase (JAK) inhibitor failure. This open-label, phase 1\/2 study evaluated bomedemstat, an irreversible inhibitor of lysine-specific demethylase 1, in participants with MF refractory or resistant to, inadequately controlled by, or intolerant of approved therapies. Eighty-nine participants initially received bomedemstat at doses 0.25, 0.5, or 0.6 mg\/kg orally once per day, titrated to achieve a target platelet count of \u226550 \u00d7 109\/L to \u226475 \u00d7 109\/L. Primary end points were safety and change in spleen volume. Hematologic response and change in symptom burden, bone marrow fibrosis score, and variant allele frequency (VAF) were exploratory. Eighty-seven (97%) participants experienced \u22651 any-cause adverse event (AE), most commonly thrombocytopenia (48%) and dysgeusia (36%); 62 (69%) participants experienced \u22651 grade 3 to 5 AE. Three participants (3%) experienced AEs that led to death; none were related to treatment. Of 35 participants with spleen volume data at week 24, 23 (66%) had a reduction in spleen volume; 9 (26%) had a reduction of \u226520%. Mean platelet and white blood cell counts normalized over 24 weeks; hemoglobin levels remained stable. Participants reported improvement in most symptoms, including fatigue. Of 35 participants with baseline and week 24 data, 8 (23%) had improved bone marrow fibrosis by \u22651 grade per central review, and 21 (60%) were stable. Of 36 participants with CALR, JAK2, or MPL mutations and data at week 24, 56% had a reduction in VAF. Bomedemstat had manageable safety and clinical activity in participants with MF in need of an alternative therapy. This trial was registered at www.ClinicalTrials.gov as NCT03136185.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018141","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:54:41Z","timestamp":1777488881000},"page":"4585-4594","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1\/2 study"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9551-4893","authenticated-orcid":false,"given":"Harinder","family":"Gill","sequence":"first","affiliation":[{"name":"1Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5293-4620","authenticated-orcid":false,"given":"Abdulraheem","family":"Yacoub","sequence":"additional","affiliation":[{"name":"2Division of Hematologic Malignancies and Cellular Therapeutics, Department of Internal Medicine, University of Kansas Cancer Center, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3422-1309","authenticated-orcid":false,"given":"Aaron T.","family":"Gerds","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Shortt","sequence":"additional","affiliation":[{"name":"4Department of Medicine, School of Clinical Sciences, Monash University and Monash Haematology, Monash Health, Clayton, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Rossetti","sequence":"additional","affiliation":[{"name":"5Division of Hematology\/Oncology, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8522-1002","authenticated-orcid":false,"given":"Adam J.","family":"Mead","sequence":"additional","affiliation":[{"name":"6Medical Research Council Weatherall Institute of Molecular Medicine and NIHR Biomedical Research Centre, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim R.","family":"G\u00f6thert","sequence":"additional","affiliation":[{"name":"7Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1011-8171","authenticated-orcid":false,"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany"},{"name":"9Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Ewing","sequence":"additional","affiliation":[{"name":"10Haematology Department, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna B.","family":"Halpern","sequence":"additional","affiliation":[{"name":"11Division of Hematology and Oncology, University of Washington Medicine, Seattle, WA"},{"name":"12Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-5668","authenticated-orcid":false,"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[{"name":"13Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli,\u201d Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8068-5289","authenticated-orcid":false,"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[{"name":"14Dipartimento di Oncologia ed Onco-Ematologia, Universit\u00e0 degli Studi di Milano, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[{"name":"15Medical Oncology and Hematology, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7615-0572","authenticated-orcid":false,"given":"Monia","family":"Marchetti","sequence":"additional","affiliation":[{"name":"16Hematology and Transplant Unit, Azienda Ospedaliera Universitaria, Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Harrison","sequence":"additional","affiliation":[{"name":"17Department of Clinical Haematology, Guy\u2019s and St Thomas\u2019 National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-0730","authenticated-orcid":false,"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"18Department of Experimental and Clinical Medicine, University of Florence, Careggi University Hospital, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Watts","sequence":"additional","affiliation":[{"name":"19Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Leonard M. Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0996-3439","authenticated-orcid":false,"given":"John C.","family":"Wood","sequence":"additional","affiliation":[{"name":"20Department of Pediatrics and Radiology, Children\u2019s Hospital Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7171-2935","authenticated-orcid":false,"given":"David M.","family":"Ross","sequence":"additional","affiliation":[{"name":"21Department of Haematology, Royal Adelaide Hospital, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Peppe","sequence":"additional","affiliation":[{"name":"22Imago BioSciences Inc, a subsidiary of Merck & Co, Inc, Rahway, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Natsoulis","sequence":"additional","affiliation":[{"name":"22Imago BioSciences Inc, a subsidiary of Merck & Co, Inc, Rahway, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Hugh Young","family":"Rienhoff","sequence":"additional","affiliation":[{"name":"22Imago BioSciences Inc, a subsidiary of Merck & Co, Inc, Rahway, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"issue":"16","key":"2026071409570525000_bib1","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood.2022017423","article-title":"Myelofibrosis","volume":"141","author":"Passamonti","year":"2023","journal-title":"Blood"},{"issue":"13","key":"2026071409570525000_bib2","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"20","key":"2026071409570525000_bib3","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.2014.57.6652","article-title":"Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study","volume":"33","author":"Hultcrantz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15","key":"2026071409570525000_bib4","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"2026071409570525000_bib5","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3390\/cancers16020313","article-title":"Myeloproliferative neoplasms: diseases mediated by chronic activation of signal transducer and activator of transcription (STAT) proteins","volume":"16","author":"Liongue","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2026071409570525000_bib6","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3324\/haematol.2015.141283","article-title":"Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies","volume":"101","author":"Zahr","year":"2016","journal-title":"Haematologica"},{"issue":"22","key":"2026071409570525000_bib7","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"2026071409570525000_bib8","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1097\/HS9.0000000000000054","article-title":"LSD1 inhibition prolongs survival in mouse models of MPN by selectively targeting the disease clone","volume":"2","author":"Jutzi","year":"2018","journal-title":"Hemasphere"},{"issue":"11","key":"2026071409570525000_bib9","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2217\/fon-2022-1298","article-title":"Defining ruxolitinib failure and transition to next-line therapy for patients with myelofibrosis: a modified Delphi panel consensus study","volume":"19","author":"Mascarenhas","year":"2023","journal-title":"Future Oncol"},{"key":"2026071409570525000_bib10","doi-asserted-by":"crossref","first-page":"106770","DOI":"10.1016\/j.leukres.2021.106770","article-title":"Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval","volume":"112","author":"Thomas","year":"2022","journal-title":"Leuk Res"},{"issue":"2","key":"2026071409570525000_bib11","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.17192","article-title":"Second primary malignancy in myelofibrosis patients treated with ruxolitinib","volume":"193","author":"Polverelli","year":"2021","journal-title":"Br J Haematol"},{"key":"2026071409570525000_bib12","doi-asserted-by":"crossref","first-page":"750346","DOI":"10.3389\/fimmu.2021.750346","article-title":"Immune dysregulation and infectious complications in MPN patients treated with JAK inhibitors","volume":"12","author":"Cattaneo","year":"2021","journal-title":"Front Immunol"},{"issue":"9","key":"2026071409570525000_bib13","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/leu.2012.157","article-title":"Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation","volume":"26","author":"Spr\u00fcssel","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"2026071409570525000_bib14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccr.2012.03.014","article-title":"The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells","volume":"21","author":"Harris","year":"2012","journal-title":"Cancer Cell"},{"key":"2026071409570525000_bib15","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours","author":"Swerdlow","year":"2017"},{"issue":"20","key":"2026071409570525000_bib16","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2026071409570525000_bib17","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"issue":"9","key":"2026071409570525000_bib18","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2026071409570525000_bib19","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"2026071409570525000_bib20","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"issue":"16","key":"2026071409570525000_bib21","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1182\/blood.2024024220","article-title":"Identifying disease-modifying potential in myelofibrosis clinical trials","volume":"144","author":"Ross","year":"2024","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4585\/2530477\/blooda_adv-2025-018141-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4585\/2530477\/blooda_adv-2025-018141-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:57:14Z","timestamp":1784037434000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/13\/4585\/568089\/The-lysine-specific-demethylase-1-LSD1-inhibitor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":21,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,7,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018141","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,14]]},"published":{"date-parts":[[2026,6,26]]}}}